Background: Cholangiocarcinoma, a malignancy originating from the bile ducts, poses significant treatment challenges due to its typically late diagnosis and limited therapeutic options. However, recent advances in molecular genetics enable more personalized treatment approaches. A notable breakthrough in this context is the identification of isocitrate dehydrogenase (IDH) mutations, particularlyIDH1andIDH2, which occur in a subset of cholangiocarcinoma patients. Those withIDH1/2mutations may benefit from targeted therapies. For instance, Ivosidenib, an IDH1 inhibitor, has shown efficacy in clinical trials, offering a new therapeutic option for patients withIDH1-mutant cholangiocarcinoma. Developing and implementing standardized protocols for testing and reporting mutation status are crucial for consistency and accuracy in clinical practice. Both the Idylla™ IDH1-2 Mutation Assay Kit as a FastTrack method and Next-Generation Sequencing (NGS) panels play critical roles in molecular characterization of cholangiocarcinoma. Methods: Under this aspect, a set of cholangiocarcinomas was tested using the Idylla™ platform regarding the respective recommended guidelines and standards of DIN EN ISO:17020 and DIN EN ISO:15198. Results: Overall, 25 clinically diagnosed intrahepatic cholangiocarcinomas or Adeno-CUPs were analyzed.IDH1/2mutations were identified in 68% (17/25) of cases using both methods, with high concordance between NGS and Idylla™ results. Discrepancies were observed in two samples, where Idylla™ detected no mutations, but NGS reportedIDH1andIDH2mutations, respectively. Conclusions: IdyllaTMoffers a rapid, user-friendly, and specific method for detectingIDH1/2mutations, ideal for immediate clinical needs. NGS, while more time-consuming and costly, provides comprehensive genetic profiles valuable for personalized medicine and research. The choice between these methods should be guided by the clinical context, resource availability, and individual patient needs. For routine diagnostics, we recommend an algorithmic approach starting with the FastTrack method followed by NGS for wildtype cases.
背景：胆管癌是一种起源于胆管的恶性肿瘤，由于其通常诊断较晚且治疗选择有限，带来了显著的治疗挑战。然而，分子遗传学的最新进展使得更个性化的治疗方法成为可能。在此背景下，一个显著的突破是异柠檬酸脱氢酶（IDH）突变的发现，特别是IDH1和IDH2突变，这些突变发生在一部分胆管癌患者中。携带IDH1/2突变的患者可能受益于靶向治疗。例如，IDH1抑制剂Ivosidenib在临床试验中显示出疗效，为IDH1突变型胆管癌患者提供了新的治疗选择。制定并实施用于检测和报告突变状态的标准化方案对于临床实践的一致性和准确性至关重要。Idylla™ IDH1-2突变检测试剂盒作为一种快速检测方法，以及下一代测序（NGS）panel，在胆管癌的分子特征分析中均发挥着关键作用。 方法：在此方面，我们依据DIN EN ISO:17020和DIN EN ISO:15198的相关推荐指南和标准，使用Idylla™平台对一组胆管癌样本进行了检测。 结果：总共分析了25例临床诊断为肝内胆管癌或腺癌原发灶不明（Adeno-CUPs）的病例。使用两种方法在68%（17/25）的病例中检测到IDH1/2突变，NGS与Idylla™结果之间具有高度一致性。在两个样本中观察到差异，Idylla™未检测到突变，而NGS分别报告了IDH1和IDH2突变。 结论：Idylla™为检测IDH1/2突变提供了一种快速、用户友好且特异的方法，非常适合即时的临床需求。NGS虽然更耗时、成本更高，但能提供全面的遗传图谱，对个性化医疗和研究具有重要价值。方法的选择应基于临床背景、资源可用性和患者个体需求。对于常规诊断，我们推荐一种算法流程：首先使用快速检测方法，然后对野生型病例进行NGS检测。
Evaluation of anIDH1/2Mutation FastTrack Assay for Patients with Cholangiocarcinoma
肿瘤(癌症)患者之家